1 / 16

Morbidity and Mortality Conference Ann Marie Lam, PGY-2 Emory University School of Medicine Family Medicine Residency Pr

Morbidity and Mortality Conference Ann Marie Lam, PGY-2 Emory University School of Medicine Family Medicine Residency Program October 14 th , 2010. Pituitary Adenoma. Macroadenoma (>1 cm) Rarely malignant Hormone overproduction/deficiency Can become locally invasive Can lead to CN palsies

armani
Télécharger la présentation

Morbidity and Mortality Conference Ann Marie Lam, PGY-2 Emory University School of Medicine Family Medicine Residency Pr

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Morbidity and Mortality ConferenceAnn Marie Lam, PGY-2Emory University School of MedicineFamily Medicine Residency ProgramOctober 14th, 2010

  2. Pituitary Adenoma • Macroadenoma (>1 cm) • Rarely malignant • Hormone overproduction/deficiency • Can become locally invasive • Can lead to CN palsies • Can lead to pituitary apoplexy • Can be associated with MEN I syndrome • Risk of recurrence

  3. Treatment • Medical therapy: correction/replacement of hormone overproduction/deficiency • Surgical therapy: decompression, resection • Radiation an option for adjunctive therapy

  4. Types of Pituitary Adenoma • Prolactinoma (PRL) (35%) • Acromegaly (GH) (20%) • Cushing Disease (ACTH) (7%) • Gonadotropin-Producing Adenoma (LH, FSH) (<1%) • Non-secretory Adenoma (30%) • TSH-Secreting Adenoma (<1%) • Diabetes Insipidus (lack of VP)

  5. Prolactinoma • Presentation: amenorrhea, galactorrhea, infertility, (in men: impotence, dec libido) • Diagnosis: PRL level >200 ng/ml, R/O prolactinemia from mass effect • Treatment (large, sympt): Bromocriptine, cabergoline (dopamine analog, inhibits PRL)

  6. Acromegaly • Presentation: coarse facial features, oily skin, carpal tunnel syndrome, OA, increased hat/glove/shoe size, DM • Diagnosis: elev ILGF-1, elev post-prandial GH on 100 g OGTT (failure to suppress GH to <2 ng/ml diagnostic) • Treatment: Octreotide SC (somatostatin analog), bromocriptine

  7. Cushing’s Disease • Presentation: truncal obesity, striae, round facies, hirsutism, HTN, DM, thin skin • Diagnosis: elev 24-hr urine cortisol, dexamethasone suppression test (1mg dex, night cortisol) • Treatment: ketoconazole (inhibits steroid synthesis)

  8. TSH-secreting adenoma • Presentation: goiter, thyrotoxicosis, visual impairment • Diagnosis: elev TSH, T3, T4 • Treatment: surgery, octreotide

  9. Non-secretory adenoma • Usually large at time of presentation • Presentation: bitemporal hemianopsia, CN defects (cav sinus compression), hypopituitarism • Evaluation: assess pituitary function, VF testing • Treatment: surgery, +/-radiation

  10. Long-term follow-up • Post-op 4-6 wks to confirm adenoma completely removed and hypersecretion resolved • Monitor yearly for recurrence, hypopituitarism

  11. Discussion • Expediency of work-up: delay in diagnostic testing, delay in initiating treatment

  12. Discussion • Expediency of work-up: delay in diagnostic testing, delay in initiating treatment • Multi-disciplinary approach led by primary team leading

  13. Discussion • Expediency of work-up: delay in diagnostic testing, delay in initiating treatment • Multi-disciplinary approach led by primary team leading • Consider transferring patient to primary care-providing team

  14. Discussion • Expediency of work-up: delay in diagnostic testing, delay in initiating treatment • Multi-disciplinary approach led by primary team leading • Consider transferring patient to primary care-providing team • Patient-oriented care

  15. Discussion • Expediency of work-up: delay in diagnostic testing, delay in initiating treatment • Multi-disciplinary approach led by primary team leading • Consider transferring patient to primary care-providing team • Patient-oriented care • Patient responsibility

  16. References • Harrison’s Principles of Internal Medicine. 16th edition. Disorders of the anterior pituitary and hypothalamus, 2005. • Ferri’s Clinical Advisor. Pituitary adenoma, 2010. • Klibanski, A. Prolactinomas. NEJM 362: 1219-1226, April 2010. • Melmed, S. Medical Progress: Acromegaly. NEJM 355: 2558-2573, Dec 2006. • Pituitary adenoma. UpToDate. Accessed 9/29/10.

More Related